DFTX NASDAQ
Definium Therapeutics, Inc.
1W: -0.3%
1M: -4.8%
3M: +89.7%
YTD: +212.7%
$41.96
-0.69 (-1.62%)
Weekly Expected Move ±8.6%
$36
$39
$43
$47
$51
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.6B
52W Range12.882-49.2
Volume1,356,593
Avg Volume4,527,111
Beta2.21
Dividend—
Analyst Ratings
Company Info
CEORobert Barrow
Employees105
SectorHealthcare
IndustryBiotechnology
IPO Date2016-11-15
Websitedefiniumtx.com
One World Trade Center
New York, NY 10007
US
New York, NY 10007
US
212 220 6633
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 â an R-enantiomer of 3,4-methylenedioxymethamphetamine â is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Latest News
Notable healthcare headlines for the week: UnitedHealth, J&J, and Intuitive Surgical in focus
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet
Psychedelic drugmakers could get boost from HHS, VA memorandum
Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?
Definium Therapeutics (NASDAQ: DFTX) raises $758M net in equity sale - Stock Titan
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sullivan Mark | S-Sale | 13,008 | $45.03 | 2026-06-25 |
| Roberts Brandi | S-Sale | 3,013 | $45.03 | 2026-06-25 |
| Barrow Robert | S-Sale | 29,208 | $45.03 | 2026-06-25 |
| Karlin Daniel | S-Sale | 10,035 | $45.03 | 2026-06-25 |
| Wiley Matthew T. | S-Sale | 2,867 | $45.03 | 2026-06-25 |